Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, pursuant to the Answer of 12 July 2014 to Question 206057, on anticoagulants, what plans the National Institute for Health and Care Excellence has to update that guidance.
The National Institute for Health and Care Excellence (NICE) regularly reviews the need to update its published guidance in order to take account of the latest available evidence.
We understand that NICE considered updating its technology appraisal guidance on bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230) in 2012 and decided, following consultation with stakeholders, to incorporate the recommendations into its clinical guideline on myocardial infarction with ST-segment elevation (CG167). The guideline was published in July 2013 and NICE has advised that it will undergo a surveillance review two years after its publication, expected in July 2015.